(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results…
Source link : https://www.medpagetoday.com/meetingcoverage/esmovideopearls/118303
Author :
Publish date : 2025-11-04 17:07:00
Copyright for syndicated content belongs to the linked Source.
